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Introduction: Oral capecitabine is an oral prodrug of 5-fluorouracil that has been integrated into the management
of multiple cancer types because of the convenience of administration and its efficacy compared with
5-fluorouracil. Capecitabine mimics the pharmacokinetics of intravenous 5-fluorouracil. While cardiac events
associated with the use of 5-fluorouracil are a well-known side effect, capecitabine-induced cardiotoxicity has only
been rarely reported.
Case presentation: We present a case of a 46-year-old woman of Greek ethnicity who presented to our institution
with an operated gastric sarcoma who experienced capecitabine-induced vasospastic angina. Primarily a clinical
diagnosis of a possible acute coronary syndrome was proposed and the patient was admitted to the hospital for
further investigation which was proved between normal limits. After a witnessed episode of angina, her prior history
of capecitabine intake and an undertaken further imaging investigation we associated anginal symptoms and signs
with vasospastic angina induced by capecitabine 36 hours prior to hospital admission.
Conclusion: Cardiologists should be aware of the potential cardiac hazards of capecitabine, especially in patients
with cardiovascular risk factors. Due to the increasing usage of capecitabine during the last years, patients should
be warned for the possibility of chest pain, particularly during the first few days of capecitabine treatment.
Specifically, patients developing acute coronary syndrome should not be retreated with capecitabine. On the other
hand, due to its promising antitumoral efficacy, its use should not be discouraged.
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Oral capecitabine is an oral prodrug of 5-fluorouracil (5-FU)
that has been integrated into the management of multiple
cancer types. Capecitabine, a thymidine phosphorylase–
activated fluoropyrimidine carbamate, is absorbed by the
gastrointestinal tract and metabolized to 5-FU by a cas-
cade of three enzymes. It is currently considered the only
universally approved orally administered 5-FU prodrug. It
belongs to a new generation of orally administered fluoro-
pyrimidines. It has been developed because of the clinical
need for efficient, tolerable and convenient agents that do
not require continuous infusion. Capecitabine is not a
cytotoxic drug itself; by a three-step enzymatic cascade, it* Correspondence: christos_gkolias@yahoo.com
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reproduction in any medium, provided the oris converted to 5-FU mainly within human cancer cells.
Capecitabine is converted by carboxylesterase in the liver
to 5′-deoxy-5-fluorocytidine and by cytidine deaminase in
the liver and tumor tissue to 5′-deoxy-5-fluorouridine.
Furthermore, it is converted by thymidine phosphorylase
to 5-FU in tumor tissue. Thymidine phosphorylase is
found in higher concentrations in tumor tissue than in
normal tissue and is upregulated by radiation in tumor
tissue, but not in normal tissue. Thus, oral capecitabine
can result in higher intratumoral and lower systemic 5-FU
concentration than bolus delivery of 5-FU. The drug
compares favorably with 5-FU in patients with colorectal
cancer and breast cancer, and it has a better toxicity pro-
file with mainly gastrointestinal and dermatologic effects.
Capecitabine shows antineoplastic activity and synergy
with other cytotoxic agents, including cyclophosphamide
and docetaxel, in animal models. Bioavailability after oral
administration is close to 100%. Although patients maytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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homes, the key to successful management of capecitabine
is the clinician’s awareness of its severe, but low in inci-
dence, adverse effects and the patient’s education, empha-
sizing compliance with the treatment plan, adverse effect
prevention and timely recognition of the drug’s toxicities.
This improved therapeutic index, along with more fa-
vorable pharmacokinetics (similar to those of protracted
infusion of 5-FU) and convenient oral administration
without the need for central venous access and an am-
bulatory infusion pump, make capecitabine particularly
appealing to use.
In particular, although cardiac events associated with the
use of 5-FU are a well- known side effect, capecitabine-
induced cardiotoxicity has only rarely been reported [1-4].
Walko et al. compiled a review of reports in the literature
describing adverse effects observed in capecitabine-treated
patients [5]. Chest pain occurred in 6% of 758 breast and
colorectal cancer patients treated with capecitabine at a
dose of 2500mg/m2 per day in two divided doses for 14
days followed by 1 week of rest. The authors concluded
that this complication is more frequent in patients who
have a history of coronary artery disease and recom-
mended close monitoring for cardiac abnormalities during
therapy. Herein we present the case of a 46-year-old
woman with an operated gastric sarcoma who presented
to our institution with capecitabine-induced vasospastic
angina.
Case presentation
A 46-year-old woman of Greek ethnicity was admitted
to the emergency room at our institution because of a
retrosternal pain episode 90 minutes before admission
that lasted approximately 10 minutes. Additionally, the
patient reported two transient episodes of chest painFigure 1 Echocardiogram obtained at the time of admission.during the previous 24 hours. The duration of each epi-
sode was estimated to be between two and ten minutes,
and spontaneous resolution was reported. During these
episodes, the symptoms included chest discomfort with
radiation to the back, malaise, nausea and sweating. Our
patient had no prior history of cardiac disease, coagulation
disorders or drug abuse, and she mentioned only one
cardiovascular risk factor (smoking). From her medical
history, we found that she is a heterozygous carrier of
β-thalassemia. She reported having gastric sarcoma with
metastatic peritoneal infiltrates. We had performed a
subtotal gastrectomy on her for this reason 2 months
prior to her current presentation. Treatment with oral
capecitabine (1500mg twice daily) was initiated 48 hours
before she was admitted to our hospital. The echocardio-
gram taken in the emergency room was within the normal
limits, including a sinus heart rate of about 62 beats per
minute (bpm) and physiological hemodynamic parameters
and negative biochemical markers for myocardial necrosis
(including cardiac troponin I (CTnI), creatine phosphoki-
nase, creatine kinase isoenzyme MB, lactate dehydrogen-
ase, and serum glutamic oxaloacetic transaminase). She
was transferred to the coronary intensive care unit (ICU)
for further observation. The echocardiogram, which was
performed when the patient was pain-free, revealed nor-
mal ventricular volume, no segmentary wall hypokinesia
with a left ventricular ejection fraction of 72%, normal
diastolic heart function, normal valve flow and absence of
pericardial effusion (Figure 1). Taking into account the
patient’s Thrombolysis in Myocardial Infarction score for
unstable angina, which was very low, she continued taking
capecitabine under uninterrupted monitoring [6]. The car-
diac enzymes for the next 24 hours were also negative for
myocardial necrosis, and consecutive electrocardiogram
(ECG) readings showed no repolarization abnormalities.
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the patient had a witnessed episode of heavy retrosternal
chest discomfort. A new ECG was taken immediately and
revealed sinus bradycardia (50bpm) with diffuse ST-
segment elevation in the anterior leads (V3 to V6) and
inferolateral leads (I, II, III, augmented vector left (aVL)
and augmented vector foot (aVF)) and peaked T-waves at
the same leads (Figure 2), suggestive of transmural ische-
mia. Her blood pressure was 150/90mmHg. Her pain sub-
sided after continuous infusion of nitroglycerin (4mg/h)
was initiated and a 5mg capsule of nifedipine was given to
the patient sublingually. The patient was symptomless
within 10 minutes. The ECG that was taken 40 minutes
afterward showed progressive recovery of ventricular re-
polarization abnormalities (Figure 3). Daily ECGs con-
firmed a normal repolarization pattern. Serum cardiac
markers, including CTnI, remained within the normal
range. Coronary and ventricular angiography performed
48 hours later revealed a normal epicardial coronary artery
tree and normal left ventricular function (Figure 4). She
was discharged without active coronary therapy. To con-
trol the oncological disease, intravenous cisplatin treat-
ment was initiated.
Discussion
Capecitabine is an oral prodrug that is converted through
a three-stage enzymatic reaction to 5-FU primarily in liverFigure 2 Electrocardiogram taken during the anginal episode in the c
(bpm)) with diffuse ST-segment elevation (arrows) in the anterior leads (V3
augmented vector foot) and peaked T-waves (dots) at the same leads are sand tumor cells. Through the years, it has gained popular-
ity as well as support from the oncologic community be-
cause of its efficacy, ease of administration and milder
toxicity profile. The cardiotoxic effects of intravenously
administered 5-FU pyrimidine analogues have been well-
described in the literature, with a reported incidence ran-
ging from 1% to 68% [7,8], whereas the cardiotoxic effects
of capecitabine, the oral formulation of 5-FU, are less fa-
miliar to cardiologists. These manifestations include acute
coronary syndrome (ACS), heart failure, hypertension,
hypotension, cardiomyopathy and arrhythmias. Myocar-
dial injury, thrombogenic effects, immunoallergic reaction
and coronary vasospasm have all been implicated in
the mechanism underlying 5-FU cardiotoxicity [9,10].
Capecitabine toxicity is thought to have the same eti-
ology as the toxicity of 5-FU, although capecitabine
and its metabolites are minimally cytotoxic in vitro
compared with 5-FU [11]. Our present case report
demonstrates that capecitabine can induce ACS. Al-
though the true incidence of this complication still has
not been defined, chest pain during capecitabine ther-
apy has been reported in 6% of patients [12]. Acute
coronary thrombosis cannot completely be excluded
by angiography. Coronary vasospasm is another mech-
anism that might possibly be involved. However, the
efficacy of vasodilating drugs given prophylactically
to patients with previous episodes of chest pain duringoronary intensive care unit. Sinus bradycardia (50 beats per minute
to V6) and inferolateral leads (I, II, III, augmented vector left and
uggestive of transmural ischemia.
Figure 3 Electrocardiogram taken 20 minutes after the patient’s pain resolved. Arrows show progressive recovery of ventricular
repolarization abnormalities.
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results [13].
Conclusion
Capecitabine should be considered a drug with cardio-
toxic potential [14], even in the absence of prior cardiac
history. It can induce coronary spasm at the macro- orFigure 4 Coronary angiography images showing normal epicardial comicrovascular level [15]. Cardiologists should be aware
of its potential cardiac hazards, which might be manifested
by coronary angiospasm, especially in patients with car-
diovascular risk factors. Because of the increasing use of
capecitabine during the past several years, patients should
be warned and informed about the possibility of chest
pain and other possible emergent anginal symptoms,ronary artery tree and normal left ventricular function.
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treatment. Most importantly, patients who develop ACS
should not be retreated with capecitabine. However, be-
cause of capecitabine’s promising antitumoral efficacy,
its use should not be discouraged.
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